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The serine/threonine protein kinase Akt, a downstream effector
of phosphoinositide 3-kinase (PI3K), plays a pivotal role in
tumorigenesis because it affects the growth and survival of
cancer cells. Several laboratories have demonstrated that Akt
inhibits transcriptional activation of a number of related fork-
head transcription factors now referred to as FoxO1, FoxO3,
and FoxO4. Akt-regulated forkhead transcription factors are
involved in the control of the expression of both the cyclin-
dependent kinase (cdk) inhibitor p27Kip1 and proapoptotic Bim
protein. Very little information is available concerning the
importance of the PI3K/Akt pathway in HL60 human leukemia
cells. Here, we present our findings showing that the PI3K/Akt
axis regulates cell cycle progression of HL60 cells through
multiple mechanisms also involving the control of FoxO1 and
FoxO3. To this end, we took advantage of a HL60 cell clone
(HL60AR cells) with a constitutively activated PI3K/Akt axis.
When compared with parental (PT) HL60 cells, HL60AR cells
displayed higher levels of phosphorylated FoxO1 and FoxO3. In
AR cells forkhead factors localized predominantly in the
cytoplasm, whereas in PT cells they were mostly nuclear. AR
cells proliferated faster than PT cells and showed a lower
amount of the cdk inhibitor p27Kip1, which was mainly found in
the cytoplasm and was hyperphosphorylated on threonine
residues. AR cells also displayed higher levels of cyclin D1 and
phosphorylated p110 Retinoblastoma protein. The protein
levels of cdk2, cdk4, and cdk6 were not altered in HL60AR
cells, whereas the activities of both ckd2 and cdk6 were higher
in AR than in PT cells. These results show that in HL60 cells the
PI3K/Akt signaling pathway may be involved in the control of
the cell cycle progression most likely through mechanisms
involving the activation of forkhead transcription factors.
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Introduction
The serine/threonine protein kinase Akt/protein kinase B (PKB) is
a pleckstrin-homology domain containing serine/threonine
kinase.1,2 Akt acts downstream of phosphoinositide 3-kinase
(PI3K). Therefore, Akt is activated upon treatment of cells with a
variety of extracellular growth factors that stimulate PI3K and
production of 30 phosphoinositide lipids.3,4 Several lines of
evidence suggest that PI3K regulates Akt activation through
the binding of phosphatidylinositol 3,4,5 trisphosphate
(PtdIns(3,4,5)P3) to the pleckstrin homology domain of Akt,
resulting in the recruitment of Akt to the cell membrane. A
conformational change of Akt then follows, allowing residues
Thr 308 and Ser 473 to be phosphorylated by upstream kinases
(reviewed in Brazil and Hemmings5). Several downstream
targets of Akt have been identified, pointing to the possible
mechanisms by which Akt promotes cell proliferation and
survival and blocks apoptosis. Akt phosphorylates and
inactivates proapoptotic proteins such as Bad and procaspase-
9.2 Akt activates NF-kB transcription factor that controls the
expression of several antiapoptotic proteins such as FLIP, XIAP,
survivin, and IAP-2 [eg Mitsiades et al 6]. Another target of Akt
is CREB transcription factor which stimulates transcription of
survival genes such as Bcl-2 and Mcl-1.2,7,8 Furthermore,
several laboratories have demonstrated that Akt inhibits
transcriptional activation of a number of related transcription
factors (FKHR/FKHRL1/AFX),9–11 now referred to as FoxO1,
FoxO3, and FoxO4.12 Each of these forkhead factors contains
phosphorylation sites for Akt, and Akt-mediated phosphoryla-
tion was shown to result in translocation of these factors from
the nucleus to the cytoplasm.10,13 Akt-regulated forkhead
transcription factors are involved in the control of the expression
of both the cyclin-dependent kinase (cdk) inhibitor p27Kip1 and
Bim, a proapoptotic member of the Bcl-2 family.14 These
findings indicate that forkhead factors play a key role in the
regulation of cell cycle progression and apoptosis. Owing to its
multiple targets, Akt is thought to play a fundamental role in
tumorigenesis.1
The PI3K/Akt pathway has been investigated in a large
variety of cell lines. Surprisingly, however, very little informa-
tion is available concerning the importance of this pathway in
HL60 cells. These cells originated from a human promyelocytic
leukemia and are a useful model for studying signal transduction
networks that which are critical for survival and proliferation
of leukemic cells. We have recently described a HL60
human leukemia cell clone (named HL60AR, for apoptosis
resistant) with a constitutively activated PI3K/Akt
axis.15 Subsequently, we have shown that HL60AR cells
are resistant to multiple chemotherapeutic drugs and all-
trans-retinoic acid (ATRA).16 Drug resistance could be lowered
by inhibitors of the PI3K/Akt signaling pathway. The activation
of the PI3K/Akt pathway in AR cells is due to an autocrine
production of insulin-like growth factor-1, a powerful stimulator
of this signaling network.16 We further demonstrated that
this clone is resistant to tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL),17 one of the latest members
of the TNF superfamily known to induce apoptosis in a
wide variety of cancer cells.18,19 TRAIL resistance of HL60AR
cells was dependent on NF-kB activation and pharmacological
inhibitors of PI3K/Akt pathway restored TRAIL sensitivity
of this clone.17 These results pointed to a key role played
by the PI3K/Akt pathway in determining resistance to conven-
tional (chemotherapy, ATRA) or novel (TRAIL) therapeutic
treatments.
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Since we observed that HL60AR cells grew faster than
parental (PT) HL60 cells, we felt they could constitute a useful
model to investigate the relevance (if any) of the PI3K/Akt
signaling in the control of the cell cycle progression of HL60
cells. Indeed, evidence collected from other cell types points to
a key role played by the PI3K/Akt pathway in governing the
molecular mechanisms necessary for cell cycle progression.4
Here, we show that HL60AR cells displayed a hyperphos-
phorylation of FoxO1 and FoxO3 transcription factors as well as
their translocation from nucleus to cytoplasm. AR cells also
showed a reduced G1 phase length. This was accompanied by a
lowered synthesis of the cdk inhibitor p27Kip1, which also
relocalized to cytoplasm and was hyperphosphorylated on
threonine residues. In addition, we detected an increase in the
amount of cyclin D1 and an enhanced phosphorylation of
the p110 Retinoblastoma (Rb) protein in HL60AR cells.
Materials and methods
Chemicals and reagents
Bovine serum albumin (BSA), propidium iodide (PI), RNase A,
RPMI 1640, fetal calf serum, normal rabbit IgG, normal mouse
IgG, normal goat serum, fluorescein isothiocyanate (FITC)-
conjugated anti-mouse IgG, and peroxidase-conjugated sec-
ondary antibodies were from Sigma (St Louis, MO, USA). The
COMPLETE Protease Inhibitor Cocktail, and the Lumi-LightPlus
enhanced chemiluminescence (ECL) detection kit were from
Roche Applied Science (Milan, Italy). Calf thymus histone H1,
wortmannin and Ly 294002 were from Calbiochem (La Jolla,
CA, USA). The Akt kinase nonradioactive assay kit and
glutathione-S-transferase (GST)-Rb-(769–921) fusion protein
were from Cell Signaling Technology (Beverly, MA, USA).
Protein A/G-Agarose was from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). [g-32P]ATP was from Amersham Pharmacia
Biotech (Uppsala, Sweden). Colloidal gold-conjugated second-
ary antibody was from British Biocell International (Cardiff, UK).
The following primary antibodies were used in this study. From
Upstate Biotechnology (Lake Placid, NY, USA): rabbit poly-
clonals to total FoxO3, and to Thr 32 phosphorylated FoxO3
(p-FoxO3). From Santa Cruz Biotechnology: rabbit polyclonals
to cyclin D1, D2, D3, E, cdk2, cdk4, and cdk6. From
Calbiochem: mouse monoclonal to human lamin B. From Cell
Signaling Technology (Beverly, MA, USA): rabbit polyclonals to
Thr 473 phosphorylated Akt (p-Akt, Catalog #9271, specific for
Western blot and immunoprecipitation), to Ser 473 p-Akt
(Catalog #9277, specific for immunohistochemistry), total Rb
protein, to Ser 780 phosphorylated Rb protein (p-Rb protein), to
Ser 795 p-Rb protein, to Ser 807/811 p-Rb protein, to total
FoxO1, to Ser 256 phosphorylated FoxO1 (p-FoxO1). From
Sigma: mouse monoclonal to b tubulin. From BD Transduction
Laboratories (San Diego, CA, USA): mouse monoclonal to
p27Kip1 (clone 57). From Alexis Biochemicals (Lausen, Switzer-
land): monoclonal antibody to phosphothreonine (clone 14B3).
Cell culture
HL60PT (for parental, obtained from the American Type Culture
Collection-CCL 240) and HL60AR (for Apoptosis Resistant) cells
were routinely maintained in RPMI 1640 supplemented with
10% fetal calf serum at an optimal cell density of 3–8
105 cells/ml. The medium was changed every 3 days. All the
results presented in this article have been obtained with cells
cultured for 2 days, unless otherwise indicated. In some
experiments, cells had been preincubated for 24 h with nontoxic
concentrations of the PI3K pharmacological inhibitors wort-
mannin (0.1 mM) or Ly294002 (10 mM).
Cell cycle analysis and determination of the G1 phase
length
To evaluate the cell cycle, 5 105 cells were fixed in 1 ml cold
70% ethanol at 41C for 1 h. The cells were centrifuged, washed
in PBS, resuspended in 0.4 ml PBS, and treated with 0.5 mg/ml
RNAse A for 1 h at 371C. After addition of 20 mg/ml of PI,
samples were analyzed with an Epics XL flow cytometer
equipped with the appropriate software (Beckman-Coulter
Immunology, Miami, FL, USA). The G1 length was estimated
by determining the doubling time and the proportion of cells in
the G1 phase. The cell number was determined at 0, 24, 48, and
72 h in culture and plotted semilogarithmically vs the time, and
the doubling time was calculated from the slope of the straight
line thus obtained. The proportion of cells in the G1 phase was
derived from the average percentage of cells in the G1 phase,
measured by flow cytometry. The length of the G1 phase was
calculated using the formula: TG1/TC¼ 1n (FG1þ 1)/ln 2 (TC is
the doubling time, TG1 is the duration of G1 and FG1 is the
fraction of cells in G1). In these experiments, when required, the
PI3K inhibitors were added to the culture media every 24 h.
Immunoprecipitation
Cells or nuclei were resuspended in 50 mM Tris-HCl, pH 7.4,
1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 1% Triton X-100,
supplemented with the COMPLETE Protease Inhibitor Cocktail
and phosphatase inhibitors (5 mM sodium pyrophosphate, 2 mM
b-glycerophosphate, 1.0 mM Na3VO4, and 20 nM okadaic acid),
then homogenized by 30 passages through a 25 gauge needle.
Cell homogenates (1 ml, containing 500 mg of protein) were
precleared by adding 5 mg of normal rabbit or mouse IgG and
10mg of 50% Protein A/G agarose, followed by incubation for
1 h at 41C and centrifugation at 12 000 g for 10 min at 41C. Then,
the samples were incubated for 2 h at 41C under constant
agitation with 5 mg of the antibody of interest. A 10mg measure
of 50% Protein A/G Agarose was then added and the incubation
was proceeded for 1 h at 41C under constant agitation.
Isolation of nuclei
Briefly, cells were washed once in PBS, pH 7.4 (without Ca2þ
and Mg2þ ) and resuspended to 1.5 107/ml in 10 mM Tris-
HCl, pH 7.4, 2 mM MgCl2, 0.5 mM phenylmethylsulfonyl
fluoride (PMSF), 10mg/ml each of aprotinin and leupeptin,
5 mM sodium pyrophosphate, 2 mM b-glycerophosphate, 1.0 mM
Na3VO4, and 20 nM okadaic acid. After 5 min at 01C, cells were
sheared by six passages through a 22 gauge needle fitted to a
30 ml plastic syringe. The concentration of Mg2þ was brought to
5 mM and nuclei were sedimented at 400 g for 6 min. The
postnuclear supernatant was saved for analysis of cytoplasmic
fraction. Nuclei were washed once in 10 mM Tris-HCl, pH 7.4,
5 mM MgCl2 and resuspended to 2 mg DNA/ml in 10 mM Tris-
HCl, pH 7.4, 0.25 M sucrose, 5 mM MgCl2. This procedure
allowed the preparation of nuclei free of cytoplasmic contami-
nation as demonstrated by transmission electron microscopy
analysis (data not shown).
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Preparations of extracts for Western blot analysis
Cells or nuclei were resuspended at B107/ml in boiling lysis
buffer containing 62.5 mM Tris-HCl, pH 6.8, 2% sodium
dodecylsulfate (SDS), 10% glycerol, 5% 2-mercaptoethanol,
and the protease and phosphatase inhibitor cocktail. Lysates
were briefly sonicated to shear DNA and reduce viscosity,
boiled for 5 min to solubilize protein, and stored at 801C until
required.
Western blot analysis
Protein (50–80mg) separated on SDS-polyacrylamide gels (SDS-
PAGE) was transferred to nitrocellulose sheets using a semidry
blotting apparatus. Sheets were saturated in PBS containing 5%
normal goat serum and 4% BSA for 60 min at 371C (blocking
buffer), then incubated overnight at 41C in blocking buffer
containing the primary antibodies. After four washes in PBS
containing 0.1% Tween-20, they were incubated for 30 min at
room temperature with the appropriate peroxidase-conjugated
secondary antibodies, diluted 1:5000 in PBS-Tween-20, and
washed as above. The bands were visualized by the ECL
method.
Akt kinase assay
This was performed according to manufacturer’s instructions.
Briefly, in this assay a polyclonal antibody was used to
selectively immunoprecipitate Akt from cell or nuclear lysates.
The resulting immunoprecipitates were incubated with GSK-3
fusion protein in the presence of ATP. This allowed Akt to
phosphorylate GSK-3. Phosphorylation of GSK-3 was measured
by Western blotting using an antibody to Ser 21/9 phosphory-
lated GSK-3a/b (p-GSK-3a/b).
Immunocomplex kinase assay
Cells were suspended in lysis buffer containing 50 mM Hepes-
NaOH, pH 7.5, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1 mM
DTT, 0.1% Tween-20, 10% glycerol, 1 mM PMSF, 10mg/ml each
of aprotinin, leupeptin, and pepstatin A, 5 mM sodium pyrophos-
phate, 2 mM b-glycerophosphate, 20 mM NaF, 1.0 mM Na3VO4,
and 20 nM okadaic acid, followed by a 10-s sonication and
clearing by centrifugation at 14 000 rpm in a microfuge for
15 min. Supernatants were assayed for protein concentration
and protein samples of 4 mg each were incubated for 4 h at 41C
with appropriate polyclonal antibodies (5 mg), then immuno-
precipitated for 1 h with 10mg of 50% Protein A/G agarose.
Immunoprecipitated proteins on beads were washed three times
with 1 ml of lysis buffer and twice with kinase reaction buffer
(50 mM Hepes-NaOH, pH 7.5, 1 mM DTT, 10 mM MgCl2, 5 mM
MnCl2, 10 mg/ml each of aprotinin, leupeptin, and pepstatin A,
0.2 mM PMSF, 20 mM NaF, 0.2 mM Na3VO4). The beads were
incubated for 30 min with 40 ml kinase reaction buffer supple-
mented with 10mM ATP, 0.4 mCi/ml [g-32P]ATP, and 40mg
substrate/ml. Histone H1 was used as kinase substrate for cdk2,
and GST-Rb was used as kinase substrate for both cdk4 and
cdk6. After incubation at 301C for 30 min, the reaction was
stopped by adding 3 boiling electrophoresis sample buffer.
The supernatant was separated SDS-PAGE and the radioactivity
was detected by autoradiography.
Immunoelectron microscopy detection of Ser 473 p-Akt
A postembedding technique was used as a method for
transmission immunoelectron microscopy. Samples were fixed
with 1% glutaraldehyde in sodium phosphate buffer, pH 7.3, for
35 min at 41C, dehydrated up to 70% ethanol and embedded in
London Resin White. Polymerization was performed overnight
at 41C by accelerator. To block nonspecific binding sites, the
grids were treated with TBS buffer (20 mM Tris-HCl, pH 8.2,
150 mM NaCl, 0.1% BSA, 0.05% Triton, 0.05% Tween-20) for
10 min at room temperature. Sections were incubated at 41C
with the primary antibody (anti-Ser 473 p-Akt, Catalog #9277)
diluted 1:50 in TBS. Grids were washed several times in TBS and
then incubated with the secondary antibody (1:50 in TBS). The
secondary antibody was an anti-rabbit IgG conjugated with
15 nm colloidal gold particles. The grids were briefly stained
with uranyl acetate (5 min) and subsequently with lead citrate
(3 min). Sections were examined with a JEOL-JEM 100S electron
microscope.
Immunofluorescent staining
Cells in media were plated onto 0.1%. poly-L-lysine-coated
glass slides, and adhesion was allowed to proceed for 30 min at
room temperature. Samples were fixed in freshly prepared 4%
paraformaldehyde in PBS for 30 min at room temperature and
then permeabilized with 0.2% Triton X-100 for 10 min. After
several washes with PBS, nonspecific binding of antibodies was
blocked by a 30 min incubation at 371C with PBS, 2% BSA, 5%
normal goat serum (NGS). Slides were then incubated for 3 h at
371C with either polyclonal antibody to Ser 473 p-Akt (specific
for immunocytochemistry) or monoclonal antibody to p27Kip1
(both diluted 1:50 in PBS, 2% BSA, 5% NGS), then washed three
times in PBS and reacted with FITC-conjugated anti-rabbit or
anti-mouse IgG, diluted 1:200 in PBS, 2% BSA, 5% NGS for 1 h
at 371C. Samples were subsequently washed three times in PBS,
stained with 0.01 mg/ml 40,6-diamidino-2-phenylindole (DAPI)
in PBS and mounted in 20 mM Tris-HCl, pH 8.2, 90% glycerol
containing 2.3% of the antifading agent 1,4-diazobicyclo–
octane. Slides were observed and photographed using a Zeiss
Axiophot epifluorescence microscope.
Results
Ser 473 p-Akt mainly localizes to the nucleus of
HL60AR cells
We recently described a HL60 cell clone (named HL60AR) with
a constitutively active PI3K/Akt pathway.15 When compared
with HL60PT cells, the AR clone displays higher levels of
phosphorylated (active) Akt.16 Since previous investigations
have highlighted that p-Akt may migrate to the nucleus
(reviewed in Neri et al 20), we sought to analyze the subcellular
distribution of Ser 473 p-Akt in HL60 PT and AR cells. As shown
in Figure 1a, Western blot analysis showed that a nearly similar
amount of Ser 473 p-Akt was detectable in the cytoplasmic
fraction prepared from either cell type. On the other hand, no
Ser 473 p-Akt immunoreactivity could be detected in nuclei
obtained from PT cells, whereas a strong immunoreactivity for
Ser 473 p-Akt was detected in the nuclear fraction prepared
from HL60AR cells. We next performed an in vitro Akt kinase
assay using both the cytoplasmic and the nuclear fraction. As
presented in Figure 1b, c, a similar amount of cytoplasmic
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activity was detected in either HL60PT or AR cells. However,
when the nuclear Akt kinase activity was assayed, it turned out
to be much higher in AR than in PT cells. To further demonstrate
that Ser 473 p-Akt was selectively concentrated in the nucleus
of HL60AR cells, we employed both immunofluorescence
and immunoelectron microscopy analysis. As shown in
Figure 2a, immunofluorescent staining revealed that Ser 473
p-Akt was detectable only in the nucleus of AR cells (compare
picture a with c). Immunogold labeling followed by transmission
electron microscope analysis demonstrated that in HL60PT
cells, a scarce immunolabeling for Ser 473 p-Akt was
Figure 1 Ser 473 p-Akt preferentially localizes to the nucleus of
HL60AR cells. Panel (a) Western blotting analysis for Ser 473 p-Akt
(active Akt) performed on cytoplasmic and nuclear fractions prepared
from HL60PT and AR cells. To detect Ser 473 p-Akt antibody #9271
was employed. Blots were probed with antibody to b tubulin or to
lamin B to ensure equal protein loading and purity of the fractions.
Protein (80mg), separated by SDS-PAGE, was blotted to each lane.
Reactive bands were revealed by ECL. A blot representative of three
separate experiments is shown. Panel (b) Akt activity assay on GSKa/b
performed on cytoplasmic and nuclear fractions prepared from
HL60PT and AR cells. Immunoprecipitation of cytoplasm or nuclear
fractions was performed with an antibody to total Akt. The
immunoprecipitates were subjected to an in vitro kinase assay using
GSK a/b as a substrate (1mg). The reaction products were resolved on a
12% SDS-PAGE and subjected to Western blot analysis using anti-
p-GSK a/b antibody. One representative experiment of three is shown.
Panel (c) relative amount of p-GSKa/b, determined by densitometric
scanning of the films. Results are mean7s.d. of three different
experiments.
Figure 2 Immunolocalization of Ser 473 p-Akt in HL60PT and AR
cells. Panel (A) immunofluorescence staining for Ser 473 p-Akt. Cells
adherent to coverslips were fixed, permeabilized and stained with an
immunocytochemistry-specific polyclonal antibody to Ser 473 p-Akt,
which was then revealed by a FITC-conjugated anti-rabbit IgG.
Samples were counterstained for DNA by DAPI. Note that the
exposure time of (a) and (c) was chosen to evidentiate nuclear
staining, if present. For this reason, the faint cytoplasmic staining is not
visible. Scale bar: 5 mM. (B) immunoelectron microscopy analysis for
Ser 473 p-Akt in HL60PT cells. (C) immunoelectron microscopy
analysis for Ser 473 p-Akt in HL60AR cells. In (B) and (C), the
arrowheads point to gold particles. Nu: nucleus. Scale bar in (B and C)
0.5mm.
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present only in the cytoplasm. In contrast, in HL60AR cells,
besides some gold particles scattered in the cytoplasm, there
was a strong immunoreactivity localized to the nucleus
(Figure 2b).
FoxO1 and FoxO3 are hyperphosphorylated
in HL60AR cells
Akt is known to directly phosphorylate a number of forkhead
transcription factors belonging to the FoxO subfamily. Phos-
phorylation of these forkhead factors results in their exclusion
from the nucleus and a subsequent inhibition in transcriptional
activation of forkhead target genes. Therefore, we wanted to
analyze whether, also in HL60 cells, regulation of FoxO activity
is mediated by PI3K/Akt signaling. In particular, we focused on
both FoxO1, which can be phosphorylated by Akt on Ser 256,
and FoxO3, which can be phosphorylated on Thr 32 by Akt. As
presented in Figure 3a, Western blots showed that the amount of
either total FoxO1 or total FoxO3 was similar in HL60PT and AR
and was not affected by treatment of AR cells with two unrelated
pharmacological inhibitors of the PI3K/Akt axis, wortmannin
and Ly294002, used at concentrations that promote inhibition of
Akt activity.16 In contrast, both Ser 256 p-FoxO1 and Thr 32
p-FoxO3 were more abundant in AR than in PT cells and were
sensitive to either wortmannin or Ly294002. We then performed
Western blot analysis of FoxO1 and FoxO3 in subcellular
fractions. The results presented in Figure 3b indicated that in PT
cells both the transcription factors were predominantly localized
in the nucleus, whereas in AR cells they were exclusively
(FoxO1) or mostly (FoxO3) cytoplasmic. In AR cells treated with
wortmannin or Ly294002, the localization of the examined
FoxO factors was essentially nuclear (Figure 3b).
Cell cycle and G1 length analyses
It is well established that the PI3K/Akt pathway controls cell
cycle progression by a number of mechanisms (reviewed in
Katso et al;4 Lawlor and Alessi21). We, therefore, set out to
analyze by flow cytometry the cell cycle of HL60PT and AR
cells. As presented in Figure 4, in the HL60AR clone there was,
after 48 h of culture, a marked increase in the quantity of cells in
either S or G2/M phase of the cell cycle when compared with PT
cells. In contrast, the percentage of cells in the G1 phase of the
cycle was higher in PT than in AR cells. Treatment of AR cells
with wortmannin or Ly294002 resulted in a dramatic decrease
of cells in S and G2/M, whereas those in G1 phase increased.
Moreover, as shown in Figure 5, the G1 transit time was shorter
in AR cells than in PT cells. Exposure of HL60AR cells to PI3 K
inhibitors considerably slowed G1 transit.
The PI3K/Akt axis influences p27Kip1 expression,
localization, and threonine phosphorylation in HL60
cells
Previous results have shown that p27Kip1 expression is con-
trolled by FoxO3 in an Akt-dependent fashion.14 p27Kip1 is a
well-known regulator of the G1/S transition through its cdk
inhibitory activity, which blocks the cells in G1 phase of the
cell cycle by preventing cdk-dependent phosphorylation of Rb
protein.22,23 To study whether p27Kip1 expression is regulated
in a PI3K/Akt-dependent manner also in HL60 cells, we
analyzed p27Kip1 protein levels in HL60PT, HL60AR, and in
HL60AR cells treated with PI3K pharmacological inhibitors. In
Figure 6a, we demonstrate by Western blot analysis a down-
regulation of p27Kip1 in AR cells when compared with PT cells.
Treatment of AR cells with wortmannin or Ly294002 resulted in
higher levels of p27Kip1. Very recent findings, obtained in breast
cancer cells, have shown that Akt also phosphorylates p27Kip1
on Thr 157 and promotes its cytoplasmic relocalization from the
nucleus.24,25 We, therefore, sought to investigate whether or not
this type of regulation might be effective also in HL60 cells. To
this end, we first immunoprecipitated p27Kip1 from whole-cell
lysates, blotted it to nitrocellulose paper and probed the blots
with a monoclonal antibody that selectively recognizes phos-
phothreonine. As shown in Figure 6b, the immunoreactivity for
phosphothreonine was much higher in HL60AR cells than in PT
cells, even if the levels of immunoprecipitated total p27Kip1
Figure 3 The activity and localization of forkhead transcription
factors are regulated via the PI3K/Akt pathway. (a) Western blot
analysis for FoxO1, Ser 256 p-FoxO1, FoxO3, and Thr 32 p-FoxO3 in
HL60 PT and AR cells, and in AR cells treated with wortmannin or
Ly294002. (b) Western blot analysis showing subcellular distribution
of FoxO1 and FoxO3 in HL60 PT and AR cells, and in AR cells treated
with wortmannin (0.1mM) or Ly294002 (10mM) for 24 h before
harvesting. In both (a) and (b) 80mg of protein was blotted to each
lane. In (b), the purity of the fractions was evaluated by immuno-
chemical analysis with antibody to b tubulin and lamin B. The blots
represent prototypical examples of experiments replicated at least
three times.
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were much lower in AR than in PT cells. If HL60AR cells had
been pretreated with either wortmannin or Ly294002, the levels
of threonine phosphorylation of p27Kip1 were very low. In
Figure 6c we present data obtained by subcellular fractionation
experiments. It was clear that in HL60PT cells, p27Kip1 was
mainly intranuclear, while in AR cells it was more abundantly
expressed in the cytoplasm. Treatment of AR cells with either
wortmannin or Ly294002 resulted in p27Kip1 being mostly
nuclear.
Since the cytoplasmic relocalization of p27Kip1 detected in
AR cells might simply be the consequence of an increased
extractability of the protein from nuclei during cell fractionation,
we performed in situ immunocytochemical fluorescence analy-
sis of p27Kip1 localization. As presented in Figure 7, p27Kip1 was
essentially nuclear in HL60PT cells, whereas it was mostly
cytoplasmic in HL60AR cells. Treatment of HL60AR cells with
wortmannin of Ly294002 restored the nuclear localization of
the protein.
The PI3KAkt pathway controls cyclin D1 expression
and p-Rb levels in HL60 cells
Evidence is now accumulating that the PI3K/Akt axis is required
for enhanced expression of cyclin D1, which is essential for cdk-
activation and thus for G1 progression.4,26 PI3K/Akt-evoked
cyclin D1 upregulation may occur through multiple mechan-
isms, including enhanced mRNA synthesis and stability,
increased mRNA translation, and stabilization of cyclin D1
protein (reviewed in Katso et al4). We, therefore, investigated
whether cyclin D1 expression was increased in HL-60AR cells.
We analyzed cyclin D1 at the level of protein by Western blot.
Indeed, the amount of cyclin D1 was higher in AR than in PT
cells and was sensitive to PI3K pharmacological inhibitors
(Figure 8). In contrast, we did not detect differences between
HL60PT and AR cells as far as the expression of cyclin D2,
cyclin D3, cyclin E, cdk2, cdk4, and cdk6 was concerned.
However, AR cells contained higher amount of Ser 780 p-Rb,
Ser 795 p-Rb, and Ser 807/811 p-Rb when compared with PT
cells, whereas the quantity of total Rb protein was unchanged in
the two types of cells. Phosphorylation of Rb protein in these
three sites was highly sensitive to wortmannin or Ly294002.
Cdk activities
We next measured cdk activities in HL60PT and AR cells. To
evaluate ckd2 activity, we immunoprecipitated cyclin E. As
shown in Figure 9, the amount of immunoprecipitable cyclin E
was unchanged in PT and AR and was not sensitive to
wortmannin or Ly294002. However, when the immunoprecipi-
tates were probed with an antibody to p27Kip1 it became evident
that the amount of this protein bound to cyclin E was much
lower in AR than in PT cells. Treatment of AR cells with PI3 K
inhibitors raised the amount of p27Kip1 associated with cyclin E.
Cdk2 activity was determined in the immunoprecipitates by
phosphorylation of histone H1, one of its principal substrates. As
shown in Figure 9, AR cells had higher cdk2 activity than PT
cells. Cdk2 activity of AR cells was markedly sensitive to
wortmannin or Ly294002. The activity of both cdk4 and cdk6
were assayed on immunoprecipitates using GST-Rb as phos-
phorylation substrate. As shown in Figure 9, the activity of cdk 4
was similar in PT and AR cells and was not sensitive to inhibitors
of the PI3K/Akt pathway. In contrast, cdk6 activity was higher in
AR than in PT cells and could be downregulated by treatment
with the pharmacological inhibitors.
Discussion
This study demonstrates for the first time that the control of two
members of the forkhead family of transcription factors, FoxO1
and FoxO3, is mediated by the PI3K/Akt axis in HL60 human
leukemia cells, and it is likely involved in the regulation of the
cell cycle progression. To reach such a conclusion, we took
advantage of a HL60 cell clone, isolated in our laboratory, with
an upregulated PI3K/Akt pathway. In HL60AR cells, Ser 473
p-Akt mainly localized to the nucleus, as demonstrated by
Western blot analysis and in vitro kinase assay performed on a
highly purified nuclear fraction, and in situ immunolabeling.
Figure 4 Cell cycle is affected by the PI3K/Akt pathway. (a) Cells
cultured for 48 h in medium after seeding were fixed by ethanol,
stained with PI and analyzed by flow cytometry. Wortmannin (0.1mM)
or Ly294002 (10 mM) was present for 24 h before fixation. Note that
cells in sub-G1 (apoptotic) are not represented. Results are mean7s.d.
of three different experiments. (b) Representative histograms showing
flow-cytometric analysis of PI-stained samples.
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This indicated that some Akt targets may reside within this
organelle. Also for this reason, we focused our attention on
forkhead transcription factors which, when they are not
phosphorylated by Akt, localize to the nucleus9–11,13 where
they negatively regulate cell proliferation and survival.27–29 We
detected no differences between HL60PT and AR cells as far as
the overall expression of both FoxO1 and FoxO3 was
concerned. However, FoxO1 and FoxO3 were hyperphos-
Figure 5 Estimation of G1 length in PT, AR, and inhibitor-exposed AR cells. Results are the mean7s.d. of three different experiments (a).
(b) Representative histograms showing flow-cytometric analysis of PI-stained samples.
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phorylated on Akt-targeted sites in HL60AR cells and the
phosphorylation levels were downregulated by two unrelated
pharmacological inhibitors of PI3K. Moreover, cell fractionation
experiments revealed a predominantly cytoplasmic localization
of FoxO1 and FoxO3 in AR cells, consistently with an Akt-
mediated phosphorylation. Taken together, these results sug-
gested that FoxO1 and FoxO3 are downstream targets of PI3K/
Akt signaling also in HL60 leukemia cells.
In mammalian cells, proliferation is under the control of
factors that regulate the transition between cell cycle stages at
two main check points.26 The first one is at the G1/S phase
transition for initiation and completion of DNA replication in
S phase.30,31 The second checkpoint is at the G2/M phase
transition and controls mitosis and cell division.32 When
Figure 6 The expression, threonine phosphorylation, and locali-
zation of p27Kip1 are regulated through the PI3K/Akt pathway. (a)
Western blot analysis for the expression levels of p27Kip1 in HL60 PT
and AR cells, and in AR cells treated with wortmannin or Ly294002.
Blots were also probed with antibody to b tubulin to ensure equal gel
loading. (b) Cells were lysed and immunoprecipitated with an
antibody to p27Kip1. The immunoprecipitates were probed with
antibodies to either p27Kip1 or phosphorylated threonine residues. (c)
Western blot analysis showing subcellular distribution of p27Kip1in
HL60 PT and AR cells, and in AR cells treated with wortmannin or
Ly294002. In both (a) and (c), 80mg of protein, run on SDS-PAGE, was
blotted to each lane. The purity of the fractions was evaluated by
immunochemical analysis with antibody to b tubulin and lamin B. The
blots are representative of three different experiments. In all the
experiments, wortmannin (0.1mM) or Ly294002 (10mM) was present
for 24 h before harvesting.
Figure 7 The subcellular localization of p27Kip1 is under the
control of the PI3K/Akt axis. Immunofluorescence staining showing
subcellular localization of p27Kip1 in HL60 PT and AR cells, and in AR
cells treated with wortmannin or Ly294002. Cells adherent to
coverslips were fixed, permeabilized and stained with a monoclonal
antibody to p27Kip1, which was then revealed by a FITC-conjugated
anti-mouse IgG. Samples were counterstained for DNA by means of
DAPI. Wortmannin (0.1mM) or Ly294002 (10 mM) was present for 24 h
prior to fixation. Scale bar: 5mM.
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compared with PT cells, HL60AR cells displayed a marked
increase in the amount of cells in either the S or G2/M phase of
the cell cycle, as evidenced by flow cytometric analysis.
Treatment with either wortmannin or Ly294002 decreased the
number of HL60AR cells in both S and G2/M phase and
increased those in G1. Furthermore, AR cells had a G1 transit
type considerably shorter than PT cells, and the length of their
G1 phase could be lengthened by wortmannin or Ly294002.
Therefore, HL60AR cells present a double advantage over
HL60PT cells because they are much less sensitive to apoptotic
stimuli16,17 and they proliferate faster.
Since recent results have shown that FoxO3 may negatively
control the expression of p27Kip1,14 a well-established regulator
of the G1/S phase transition, we analyzed its expression by
Western blot. p27Kip1 is a direct inhibitor of cdk2, one of the
cdks responsible for the activation of E2F1 transcription factors
that promote DNA replication.33 We have found that p27Kip1
levels are lower in HL60AR cells when compared with PT cells.
Also, the expression of p27Kip1was sensitive to wortmannin and
Ly294002, indicating an involvement of the PI3K/Akt axis in the
control of p27Kip1 protein levels. However, the decreased
expression of p27Kip1 is not the only factor that could explain
the observed differences between HL60 PT and AR cells as far as
cell cycle progression was concerned. Indeed, we have also
found that in HL60AR cells p27Kip1 is mainly localized in the
cytoplasm, whereas in PT cells it is predominantly located in the
nucleus. Furthermore, in HL60 cells p27Kip1 is hyperphos-
phorylated on threonine residues and this phosphorylation was
inhibited by either wortmannin or Ly294002. These results
strongly suggested that p27Kip1 is a direct target of the PI3K/Akt
axis in HL60 cells in agreement with recent finding by others,
obtained in breast tumors.24,25,34 Indeed, it has been shown that
Figure 8 The PI3K/Akt axis controls cyclin D1 expression and
phosphorylation of 110 kDa Rb protein. Western blot analysis for G1
cyclins (cyclin D1, D2, D3, E), cdks, total Rb and p-Rb forms in HL60
PT and AR cells, and in AR cells treated with wortmannin or
Ly294002. Blots were also probed with antibody to b tubulin to ensure
equal gel loading (80mg/lane). Immunoreactive bands were revealed
by ECL. In all the experiments, wortmannin (0.1mM) or Ly294002
(10mM) was present for 24 h before harvesting. All the blots are
representative of three separate experiments.
Figure 9 The activity of cdk2 and cdk6 is under the control of the
PI3K/Akt axis. (a) cyclin E was immunoprecipitated from lysed cells by
a specific polyclonal antibody, then the blots were probed with
antibody to either cyclin E or p27Kip1; cyclin E-associated ckd2 activity
was assayed on immunoprecipitates in vitro using histone H1 as
substrate. (b) cdk4 was immunoprecipitated from lysed cells by a
specific polyclonal antibody and its activity was determined in vitro
using GST-Rb as a substrate in an immunocomplex assay. (c) cdk6 was
immunoprecipitated from lysed cells by a specific polyclonal antibody
and its activity was determined in vitro using GST-Rb as a
phosphorylation substrate. (a), (b), and (c) are representative of three
separate experiments.
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Akt phosphorylates p27Kip1 both in vitro and in vivo and
phosphorylation occurs on a threonine residue (Thr 157) within
the nuclear localization signal (NLS) of p27Kip1,34 so that
nuclear import of p27Kip1 is impaired. Viglietto et al24 were able
to generate an antibody that specifically recognizes the Akt-
phosphorylated Thr 157 of p27Kip1. Even though we could not
use an antibody specific for Thr 157-phosphorylated p27Kip1,
our results, obtained with an antibody raised to phosphorylated
threonine residues, strongly suggested that, also in HL60AR
cells, p27Kip1 is a target of the PI3K/Akt pathway and this results
in its relocation from nucleus to cytoplasm. So far, a shifted
location of p27Kip1 from nucleus to cytoplasm has been
observed in carcinomas of breast, thyroid, esophagus, and
colon,35 but our findings point to the likelihood that it may be a
feature of other types of neoplasia.
Nevertheless, there is yet another reason that may explain
why HL60AR cells have a cell cycle progression faster than PT
cells. Indeed, they express higher levels of cyclin D1 and, as a
consequence, a higher level of p110 p-Rb protein. In contrast,
the levels of cyclin D2, D3, and E, as well as those of cdk2,
cdk4, and cdk6 were similar in PT and AR cells. Enhanced levels
of cyclin D1 and hyperphosphorylation of p110 Rb protein
detected in AR cells were sensitive to wortmannin or Ly294002,
an observation which indicates their dependency on the PI3K/
Akt axis. Both cyclin D in complex with cdk4 or cdk6 and
cyclin E-cdk2 phosphorylate p110 Rb protein, a well-known
tumor suppressor. The tumor suppressor activity of Rb protein
relies on gating S phase entry through its ability to repress genes
activated by the E2F family of transcription factors.36 In fact,
p-Rb releases members of the E2F family that play an integral
role in cell cycle progression by inducing the expression of
genes required for S phase entry.
Consistently with a downregulation and cytoplasmic reloca-
lization of p27Kip1, AR cells had higher levels of cyclin E-bound
cdk2 activity. They also showed enhanced ckd6 activity,
presumably due to upregulation of cyclin D1, whereas cdk4
activity was the same in either PT or AR cells and was not
sensitive to treatment of AR cells with PI3 K inhibitors. Previous
results have indicated that the levels of p27Kip1 were decreased,
whereas those of cyclin D1, D2, D3, and E were elevated, in
HL60 cells resistant to 1,25-dihydroxyvitamin D3 when
compared with sensitive cells.37,38 Accordingly, our HL60AR
cells are resistant to ATRA16 and displayed lower levels of
p27Kip1 and a higher amount of cyclin D1 when compared with
ATRA-sensitive (PT) cells.
Previous findings from our laboratory have highlighted the
importance of the NF-kB transcription factor in determining
HL60AR cell resistance to TRAIL,17 while those reported in this
paper have underscored the key role for forkhead transcription
factors in regulating cell cycle progression in the same cell
clone. As far as a possible CREB activation was concerned, our
unpublished findings have revealed that the activity of this PI3K/
Akt-dependent transcription factor is not upregulated in
HL60AR cells.
So far, the PI3K/Akt pathway has been scarcely investigated in
patients suffering from acute leukemia. It should be considered,
however, that there are some cases of acute myeloid leukemia
in which the PTEN tumor suppressor is absent or nonfunc-
tional.39–41 Since PTEN is a fundamental negative regulator of
Akt activity,42 it might be that in these leukemias the Akt
pathway is upregulated with a consequent resistance to multiple
apoptotic stimuli and high proliferation rates. Moreover, very
recent evidence has shown the occurrence of a possible
dominant-negative mutation of the SHIP gene in acute myeloid
leukaemia.43 SHIP is a hematopoietic-specific inhibitory phos-
phatase44 which dephosphorylates phosphatidylinositol
(3,4,5)P3 to phosphatidylinositol (3,4)P2, thus negatively influ-
encing Akt activity.
Overall, our findings are in agreement with those of other
laboratories that have recently demonstrated the importance of
the PI3K/Akt/FoxO factor pathway in controlling the prolifera-
tion of both human and murine hematopoietic cells lines14,45,46
as well as of human freshly isolated T cells14 or CD34þ
hematopoietic progenitors cells treated with erythropoietin.47
Intriguingly, it has also been shown that FoxO1 is a downstream
effector of STI 571-induced cell cycle arrest in the KCL22 cell
line established from the bone marrow of a patient with blastic
crisis of bcr-abl-positive chronic myelogenous leukemia.48
Consistently, exposure of these cells to STI 571 led to
overexpression of p27Kip1. Therefore, we may infer that our
findings are not restricted to a single cell line.
In light of this, in the future, pharmacological inhibitors of
PI3K/Akt axis might prove very valuable for slowing down the
growth rate of certain types of human leukemia other than for
sensitizing them to therapeutic agents.
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